Related Experiment Video
Updated: Aug 8, 2026

04:24
Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease
Published on: September 5, 2025
[Efficacy evidence in occupational medicine]
1SA di Epidemiologia AUSL 10 di Firenze, Italy. alberto.baldasseroni@asf.toscana.it
Summary
This study overviews the development of Evidence Based Occupational Health (EBOH). It traces the origins of evidence-based practices and discusses recent EBOH advancements in Europe and domestically.
Area of Science:
- Occupational Health
- Evidence-Based Practice
- Public Health
Context:
- The evolution of evidence-based medicine and health services, originating in the 1980s with contributions from Donabedian and Vuori for the WHO.
- The significant influence of the Cochrane Collaboration in promoting evidence-based approaches.
- The growing momentum towards integrating evidence-based principles into occupational health.
Purpose:
- To provide an overview of the key features defining the development of Evidence Based Occupational Health (EBOH).
- To explore the historical roots of evidence-based practices in healthcare.
- To discuss contemporary advancements and applications of EBOH in European and national contexts.
Summary:
- The paper outlines the foundational principles and historical trajectory of Evidence Based Occupational Health (EBOH).
- It highlights the contributions of key figures and organizations to the evidence-based movement.
- Recent developments and the current state of EBOH in Europe and specific countries are examined.
Impact:
- Facilitates a better understanding of the Evidence Based Occupational Health (EBOH) movement.
- Informs researchers and practitioners about the evolution and current status of EBOH.
- Supports the adoption and implementation of evidence-based strategies in occupational health settings.
Related Concept Videos
Dose-Response Relationship: Potency and Efficacy
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...
Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Antimicrobial Effectiveness
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
